Ripretinib (1 brand name, 1 dosage form, 1 route)
Available dosage forms: TABLET.
Routes of administration: ORAL.
Brand Names
- QINLOCK
Indications and Usage
QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Contraindications
None.
Adverse Reactions
The following clinically significant adverse reactions are discussed elsewhere in the labeling: Palmar-Plantar Erythrodysesthesia Syndrome [see Warnings and Precautions (5.1)] New Primary Cutaneous Malignancies [see Warnings and Precautions (5.2)] Hypertension [see Warnings and Precautions (5.3)] Cardiac Dysfunction [see Warnings and Precautions (5.4)] Photosensitivity [see Warnings and Precautions (5.6)]
Mechanism of Action
Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.